CLINICAL TRIALS AND OBSERVATIONS Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
نویسندگان
چکیده
*John P. Leonard,1 *Ann S. LaCasce,2 Mitchell R. Smith,3 Ariela Noy,4 Lucian R. Chirieac,5 Scott J. Rodig,5 Jian Q. Yu,6 Shankar Vallabhajosula,7 Heiko Schoder,8 Patricia English,9 Donna S. Neuberg,10 Peter Martin,1 Michael M. Millenson,3 Scott A. Ely,11 Rachel Courtney,9 Naveed Shaik,9 Keith D. Wilner,9 Sophia Randolph,9 Annick D. Van den Abbeele,12 Selina Y. Chen-Kiang,11 Jeffrey T. Yap,12,13 and Geoffrey I. Shapiro14,15
منابع مشابه
CDK4/6 inhibitor: from quiescence to senescence
The CDK4 and CDK6 kinases (CDK4/6) are the first cyclin dependent kinases to be activated and initiate transition through G1 phase of the cell cycle. In response to mitogenic growth factors, the CDK4/6 kinase together with one of three D-type cyclins (D1, D2, D3) initiates G1 progression by virtue of its capacity to phosphorylate the retinoblastoma protein (RB), a bona fide tumor suppressor and...
متن کاملCDK4/6 inhibition: the late harvest cycle begins
Effective and safe pharmacologic inhibition of the cyclin dependent kinases (CDKs) has been a goal of cancer researchers for many years. CDKs are attractive therapeutic targets in cancer for two main reasons first, some tumors harbor dependencies on particular CDKs for their initiation and maintained growth; second, there is a surprising amount of redundancy between various CDKs in maintaining ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/ bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster,1,2 Martin Dreyling,1 Wolfram Klapper,3 Christian Gisselbrecht,4 Achiel van Hoof,5 Hanneke C. Kluin-Nelemans,6 Michael Pfreundschuh,7 Marcel Reiser,8 Bernd Metzner,9 Hermann Einsele,10 Norma Peter,11 Wolfram Jung,12 Bernhard Wörmann,13 Wolf-Dieter Ludwig,14 Ulrich Dührsen,15 Hartmut Eimermacher,16 Hannes Wandt,17 Joerg Hasford,2 Wolfgang Hiddemann,1 and Michael Unterhalt,1 for the Ge...
متن کاملRapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation
Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a CDK4/6i-based trial, as first-line therapy in metastatic breast cancer, developed rapid disease progression following discontinuation of study drug while receiving standard second-line therapy off trial. We thus sought to...
متن کامل